01/25/23 8:05 AMNasdaq, OTC : ENSC, ENSCW clinical triallow floatEnsysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 StudyEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improveRHEA-AInegative
01/23/23 8:05 AMNasdaq, OTC : ENSC, ENSCW conferenceslow floatEnsysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth InvitationalEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Chief ExecutiveRHEA-AIneutral
01/11/23 8:00 AMNasdaq, OTC : ENSC, ENSCW low floatEnsysce Biosciences Issues 2023 Shareholder LetterEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter toRHEA-AIneutral
01/04/23 8:05 AMNasdaq, OTC : ENSC, ENSCW low floatEnsysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential TrialEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, todayRHEA-AIneutral
12/19/22 8:05 AMNasdaq, OTC : ENSC, ENSCW low floatEnsysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose ProtectionEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improveRHEA-AInegative
12/07/22 8:00 AMNasdaq, OTC : ENSC, ENSCW offeringlow floatEnsysce Biosciences Announces Pricing of $4.1 Million Public OfferingEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC),(OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the pricingRHEA-AIneutral
12/05/22 8:05 AMNasdaq, OTC : ENSC, ENSCW low floatEnsysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part AEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC),(OTC PINK:ENSCW), a clinical-stage biotech companyRHEA-AInegative
11/14/22 4:30 PMNasdaq, OTC : ENSC, ENSCW earningslow floatEnsysce Biosciences Reports Third Quarter 2022 Financial ResultsEnsysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safetyRHEA-AIneutral
11/14/22 8:05 AMNasdaq, OTC : ENSC, ENSCW clinical triallow floatEnsysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformativeRHEA-AIneutral
10/31/22 8:05 AMNasdaq, OTC : ENSC, ENSCW clinical triallow floatEnsysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release ProductEnsysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused onRHEA-AIneutral
